HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Finds Ingredient's IND Past After Signing Off For Supplement Use

This article was originally published in The Rose Sheet

Executive Summary

Supplement industry stakeholders say FDA makes an unjustifiable regulatory move by stating that the widely used dietary supplement ingredient is noncompliant, while the finding compels the agency to reverse its earlier acceptance of NDI notifications for vinpocetine.

Advertisement

Related Content

Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
GOP Request To Stall New Rules: Post-Election Business As Usual On Capitol Hill
Hatch Questions FDA Motive, Process In Proposed Vinpocetine Ban
Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry
New Wrinkle In NDI Debate: Supplement Ingredients Used As Drugs Outside US
Researchers Match Supplement Ingredients With Foreign Prescriptions
Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient
FDA Clear On Supplement Ingredient Petitions, But Still Fuzzy On Sec. 912

Topics

Advertisement
UsernamePublicRestriction

Register

RS108538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel